Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 8/20 | 0.70 |
| ▸ | PRKCA | P17252 | 1/20 | 0.58 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.58 |
| ▸ | HTR7 | P34969 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | CNR1 | P21554 | 2/20 | 0.44 |
| ▸ | CNR2 | P34972 | 2/20 | 0.44 |
| ▸ | CBLB | Q13191 | 3/20 | 0.42 |
| ▸ | CYP2A13 | Q16696 | 4/20 | 0.41 |
| ▸ | DHODH | Q02127 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30153039 | 0.89 | KCNH2 (0.71) | KCNH2PRKCAPTPN2HTR7CYP2D6 | |
| SCHEMBL13504954 | 0.83 | KCNH2 (0.50) | KCNH2PRKCAPTPN2HTR7CYP3A4 | |
| SCHEMBL8027494 | 0.82 | KCNH2 (0.81) | KCNH2PRKCAPTPN2HTR7 | |
| SCHEMBL1769576 | 0.82 | KCNH2 (0.62) | KCNH2PRKCAPTPN2HTR7 | |
| SCHEMBL13016557 | 0.80 | KCNH2 (0.74) | KCNH2PRKCAPTPN2HTR7 | |
| SCHEMBL1769634 | 0.80 | KCNH2 (1.00) | KCNH2PRKCAPTPN2HTR7 | |
| SCHEMBL1769673 | 0.80 | KCNH2 (1.00) | KCNH2PRKCAPTPN2HTR7 | |
| SCHEMBL3777490 | 0.79 | KCNH2 (0.58) | KCNH2PRKCAPTPN2HTR7 | |
| SCHEMBL6888447 | 0.79 | PRKCA (0.77) | KCNH2PRKCAPTPN2HTR7 | |
| SCHEMBL7999079 | 0.78 | KCNH2 (0.56) | KCNH2PRKCAPTPN2HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2244577-B1 | QUINOLIZIDINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME (US) | 2012-10-31 | — | — | EP | claimed |
| US-8273737-B2 | Quinolizidinone M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2012-09-25 | — | — | US | claimed |
| US-20110112077-A1 | Quinolizidinone m1 Receptor Positive Allosteric Modulators | MERCK SHARP & DOHME CORP. (US) | 2011-05-12 | — | — | US | claimed |
| EP-2244577-B1 | QUINOLIZIDINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME (US) | 2012-10-31 | — | — | EP | disclosed |
| EP-2244577-B1 | QUINOLIZIDINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME (US) | 2012-10-31 | — | — | EP | disclosed |
| US-8273737-B2 | Quinolizidinone M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2012-09-25 | — | — | US | disclosed |
| US-8273737-B2 | Quinolizidinone M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2012-09-25 | — | — | US | disclosed |
| US-8273737-B2 | Quinolizidinone M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2012-09-25 | — | — | US | disclosed |
| US-20110112077-A1 | Quinolizidinone m1 Receptor Positive Allosteric Modulators | MERCK SHARP & DOHME CORP. (US) | 2011-05-12 | — | — | US | disclosed |
| US-20110112077-A1 | Quinolizidinone m1 Receptor Positive Allosteric Modulators | MERCK SHARP & DOHME CORP. (US) | 2011-05-12 | — | — | US | disclosed |
| US-20110112077-A1 | Quinolizidinone m1 Receptor Positive Allosteric Modulators | MERCK SHARP & DOHME CORP. (US) | 2011-05-12 | — | — | US | disclosed |
| EP-2244577-A1 | QUINOLIZIDINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | Merck Sharp & Dohme Corp. (US) | 2010-11-03 | — | — | EP | disclosed |
| WO-2009094279-A1 | QUINOLIZIDINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK & CO., INC. (US) | 2009-07-30 | — | — | WO | disclosed |
| WO-2009094279-A1 | QUINOLIZIDINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK & CO., INC. (US) | 2009-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112077-A1 | Quinolizidinone m1 Receptor Positive Allosteric Modulators | CHRM1, CHRM2, OPRL1 | KCNH2 501/4885PRKCA 1687/4885PTPN2 1471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.